VALVE SOLUTIONSTISSUE HEART VALVES (THV)
Our latest aortic valve replacement solution for optimizing key clinical outcomes and the possibilities for patient lifetime management.
BUILT ON THE EPIC™PLATFORM THAT HAS STOOD THE TEST OF TIME
AT 10 YEARS
OVER 11.000 PATIENTS
94.6%*
Epic™ Supra Valve
Freedom From All-Cause
Reintervention2
OVER 1.900 PATIENTS
96.3%*
Epic™ Supra Valve
Freedom from SVD
(Structural Valve Degeneration)
All patient age3
FIND OUT MORE:
COMMITED TO VALVE-IN-VALVE* FOLLOW-UP DATA
3-YEAR OUTCOMES OF VALVE-IN-VALVE INTERVENTION IN A U.S. POPULATION
>95.0%
Epic™ Supra Valve
Patients Experienced Freedom
from Valve Intervention4
OPTIMIZE OUTCOMES WITH EXCELLENT HEMODYNAMICS
ESTIMATED MEAN PRESSURE GRADIENT AT 1 YEAR FOR EPIC MAX (mm Hg)1
MEAN PRESSURE GRADIENT PREDICTED BASED ON MATCHED STENT ID FOR BIOCOR/EPIC™ VALVES.
Maximizing the internal orifice provides large effective orifice areas (EOAs) and low gradients to reduce the burden on the heart and contribute to better patient outcomes.
Clinical Case clubs | Educational tools | Hot topics
Expert opinions | Live & online discussions
TV
- [a] Biocor IFU [b] Maitland, Andrew, Gregory M. Hirsch, and Edward A. Pascoe. “Hemodynamic Performance of the St. Jude Medical Epic™ Supra Aortic Stented Valve.” Journal of Heart Valve disease 20.3 (2011): 327. [c] Epic Plus IFU
- Wiechmann, RJ., et. al. Ten-year Outcomes of Surgical Aortic Valve Replacement with a Contemporary Supra Annular Porcine Valve in a Medicare Population. JTCVS Open. 2022, doi.org/10.1016/j.xjon.2022.08.002.
- Lehmann S, Merk DR, Etz CD, Oberbach A, Uhlemann M, Emrich F et al. Porcine xenograft for aortic, mitral and double valve replacement: long-term results of 2544 consecutive patients. Eur J Cardiothorac Surg 2016;49:1150–6.
- H. Kenith Fang, et al. Three-Year Outcomes of Valve-in-Valve Intervention within the Epic™ Supra and Epic™ Mitral Valves in a Medicare Population. TVT Conference 2022; Chicago, USA; June 9th, 2022.